Joel Beatty
Stock Analyst at Baird
(4.28)
# 473
Out of 4,761 analysts
183
Total ratings
42.86%
Success rate
20.38%
Average return
Main Sectors:
Stocks Rated by Joel Beatty
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CPRX Catalyst Pharmaceuticals | Initiates: Outperform | $28 | $21.62 | +29.51% | 1 | Feb 4, 2025 | |
| DNLI Denali Therapeutics | Initiates: Outperform | $31 | $20.73 | +49.54% | 1 | Jan 7, 2025 | |
| EDIT Editas Medicine | Maintains: Outperform | $10 → $8 | $1.92 | +316.67% | 3 | Dec 13, 2024 | |
| PTCT PTC Therapeutics | Maintains: Outperform | $52 → $70 | $50.69 | +38.09% | 14 | Dec 3, 2024 | |
| DRUG Bright Minds Biosciences | Initiates: Outperform | $75 | $35.99 | +108.39% | 1 | Nov 25, 2024 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $154 → $162 | $136.01 | +19.11% | 3 | Nov 18, 2024 | |
| AMLX Amylyx Pharmaceuticals | Upgrades: Outperform | $3 → $11 | $3.30 | +233.33% | 4 | Nov 18, 2024 | |
| IMMP Immutep | Maintains: Outperform | $6 → $7 | $1.92 | +264.58% | 5 | Nov 15, 2024 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $112 → $116 | $137.75 | -15.79% | 3 | Nov 13, 2024 | |
| NGNE Neurogene | Maintains: Outperform | $54 → $72 | $17.36 | +314.75% | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $515 → $650 | $644.48 | +0.86% | 5 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $72 → $65 | $68.25 | -4.76% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $32 | $7.59 | +321.61% | 1 | Oct 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $240 → $175 | $74.92 | +133.58% | 4 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $9 | $7.31 | +23.12% | 4 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $10 | $8.00 | +25.00% | 3 | Sep 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $3.19 | +401.57% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $112 → $127 | $92.25 | +37.67% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $58 | $23.67 | +145.04% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $38 | $35.32 | +7.59% | 2 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $72 | $42.59 | +69.05% | 4 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $27 | $7.63 | +253.87% | 1 | May 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $45 → $20 | $1.05 | +1,804.76% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $28 | $19.95 | +40.35% | 3 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $117 | $74.49 | +57.07% | 1 | May 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $4.5 | $2.57 | +75.10% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $83 → $103 | $128.60 | -19.91% | 2 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $16.87 | +48.19% | 3 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $9 | $0.48 | +1,774.22% | 2 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $28 | $16.38 | +70.94% | 2 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $8.59 | +86.26% | 1 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $5.15 | +35.92% | 1 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $1.25 | $1.79 | -30.17% | 2 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $44 | $3.08 | +1,328.57% | 3 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $58 | $19.90 | +191.46% | 6 | Feb 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $24 | $21.85 | +9.84% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $18 | $17.77 | +1.29% | 3 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $6 | $4.75 | +26.32% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $46 → $31 | $1.38 | +2,146.38% | 3 | Jun 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $36 → $28 | $9.57 | +192.58% | 2 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $170 → $175 | $250.59 | -30.16% | 2 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 | $4.43 | +216.03% | 8 | Jan 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $108 | $106.28 | +1.62% | 10 | Jan 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $78 | $32.32 | +141.34% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $4.40 | +2,175.31% | 2 | Apr 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $6 | $0.59 | +918.50% | 14 | Apr 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $15 | $0.47 | +3,111.30% | 2 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $1.82 | - | 12 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $15 | $7.99 | +87.73% | 11 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $120 | $1.09 | +10,909.17% | 2 | Aug 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $19 | $8.25 | +130.30% | 3 | Nov 10, 2017 |
Catalyst Pharmaceuticals
Feb 4, 2025
Initiates: Outperform
Price Target: $28
Current: $21.62
Upside: +29.51%
Denali Therapeutics
Jan 7, 2025
Initiates: Outperform
Price Target: $31
Current: $20.73
Upside: +49.54%
Editas Medicine
Dec 13, 2024
Maintains: Outperform
Price Target: $10 → $8
Current: $1.92
Upside: +316.67%
PTC Therapeutics
Dec 3, 2024
Maintains: Outperform
Price Target: $52 → $70
Current: $50.69
Upside: +38.09%
Bright Minds Biosciences
Nov 25, 2024
Initiates: Outperform
Price Target: $75
Current: $35.99
Upside: +108.39%
Jazz Pharmaceuticals
Nov 18, 2024
Maintains: Outperform
Price Target: $154 → $162
Current: $136.01
Upside: +19.11%
Amylyx Pharmaceuticals
Nov 18, 2024
Upgrades: Outperform
Price Target: $3 → $11
Current: $3.30
Upside: +233.33%
Immutep
Nov 15, 2024
Maintains: Outperform
Price Target: $6 → $7
Current: $1.92
Upside: +264.58%
Axsome Therapeutics
Nov 13, 2024
Maintains: Outperform
Price Target: $112 → $116
Current: $137.75
Upside: -15.79%
Neurogene
Nov 12, 2024
Maintains: Outperform
Price Target: $54 → $72
Current: $17.36
Upside: +314.75%
Nov 1, 2024
Downgrades: Neutral
Price Target: $515 → $650
Current: $644.48
Upside: +0.86%
Oct 30, 2024
Maintains: Neutral
Price Target: $72 → $65
Current: $68.25
Upside: -4.76%
Oct 22, 2024
Initiates: Outperform
Price Target: $32
Current: $7.59
Upside: +321.61%
Oct 21, 2024
Maintains: Outperform
Price Target: $240 → $175
Current: $74.92
Upside: +133.58%
Oct 9, 2024
Maintains: Neutral
Price Target: $13 → $9
Current: $7.31
Upside: +23.12%
Sep 5, 2024
Maintains: Neutral
Price Target: $8 → $10
Current: $8.00
Upside: +25.00%
Sep 4, 2024
Initiates: Outperform
Price Target: $16
Current: $3.19
Upside: +401.57%
Aug 2, 2024
Maintains: Outperform
Price Target: $112 → $127
Current: $92.25
Upside: +37.67%
Jul 26, 2024
Initiates: Outperform
Price Target: $58
Current: $23.67
Upside: +145.04%
Jul 25, 2024
Maintains: Outperform
Price Target: $37 → $38
Current: $35.32
Upside: +7.59%
May 31, 2024
Maintains: Outperform
Price Target: $68 → $72
Current: $42.59
Upside: +69.05%
May 28, 2024
Initiates: Outperform
Price Target: $27
Current: $7.63
Upside: +253.87%
May 15, 2024
Maintains: Outperform
Price Target: $45 → $20
Current: $1.05
Upside: +1,804.76%
May 9, 2024
Maintains: Outperform
Price Target: $31 → $28
Current: $19.95
Upside: +40.35%
May 1, 2024
Initiates: Outperform
Price Target: $117
Current: $74.49
Upside: +57.07%
Apr 30, 2024
Downgrades: Neutral
Price Target: $4.5
Current: $2.57
Upside: +75.10%
Apr 17, 2024
Maintains: Outperform
Price Target: $83 → $103
Current: $128.60
Upside: -19.91%
Apr 11, 2024
Maintains: Outperform
Price Target: $24 → $25
Current: $16.87
Upside: +48.19%
Mar 19, 2024
Maintains: Outperform
Price Target: $11 → $9
Current: $0.48
Upside: +1,774.22%
Oct 3, 2023
Maintains: Outperform
Price Target: $32 → $28
Current: $16.38
Upside: +70.94%
Jun 1, 2023
Initiates: Outperform
Price Target: $16
Current: $8.59
Upside: +86.26%
May 23, 2023
Initiates: Outperform
Price Target: $7
Current: $5.15
Upside: +35.92%
May 2, 2023
Maintains: Outperform
Price Target: $4 → $1.25
Current: $1.79
Upside: -30.17%
Apr 13, 2023
Initiates: Outperform
Price Target: $44
Current: $3.08
Upside: +1,328.57%
Feb 7, 2023
Maintains: Outperform
Price Target: $60 → $58
Current: $19.90
Upside: +191.46%
Nov 18, 2022
Maintains: Outperform
Price Target: $18 → $24
Current: $21.85
Upside: +9.84%
Nov 10, 2022
Downgrades: Underperform
Price Target: $18
Current: $17.77
Upside: +1.29%
Aug 29, 2022
Maintains: Outperform
Price Target: $9 → $6
Current: $4.75
Upside: +26.32%
Jun 1, 2022
Maintains: Outperform
Price Target: $46 → $31
Current: $1.38
Upside: +2,146.38%
Mar 3, 2022
Upgrades: Neutral
Price Target: $36 → $28
Current: $9.57
Upside: +192.58%
Feb 12, 2021
Downgrades: Neutral
Price Target: $170 → $175
Current: $250.59
Upside: -30.16%
Jan 14, 2021
Downgrades: Neutral
Price Target: $14
Current: $4.43
Upside: +216.03%
Jan 12, 2021
Downgrades: Neutral
Price Target: $108
Current: $106.28
Upside: +1.62%
Aug 10, 2020
Maintains: Buy
Price Target: $80 → $78
Current: $32.32
Upside: +141.34%
Apr 6, 2020
Maintains: Buy
Price Target: $140 → $100
Current: $4.40
Upside: +2,175.31%
Apr 1, 2020
Maintains: Buy
Price Target: $24 → $6
Current: $0.59
Upside: +918.50%
Mar 26, 2020
Maintains: Buy
Price Target: $16 → $15
Current: $0.47
Upside: +3,111.30%
Mar 17, 2020
Upgrades: Buy
Price Target: n/a
Current: $1.82
Upside: -
Sep 24, 2019
Maintains: Buy
Price Target: $19 → $15
Current: $7.99
Upside: +87.73%
Aug 17, 2018
Maintains: Neutral
Price Target: $240 → $120
Current: $1.09
Upside: +10,909.17%
Nov 10, 2017
Maintains: Buy
Price Target: $15 → $19
Current: $8.25
Upside: +130.30%